Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.
Clarke, Noel W
AffiliationDepartment of Medicine, Duke Cancer Institute, Durham NC, United StatesDepartment of Oncology, Johns Hopkins University, Baltimore MD, United States
MetadataShow full item record
CitationNaming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. 2017, Ann Oncol
JournalAnnals of Oncology
- Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.
- Authors: Pezaro CJ, Omlin A, Mastris K, ANZUP Consumer Advisory Panel., Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S
- Issue date: 2017 Aug 1
- Treating metastatic prostate cancer now and in the future.
- Authors: Meng MV, Boughey JC
- Issue date: 2014 Sep
- Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.
- Authors: Tsao CK, Galsky MD, Oh WK
- Issue date: 2014 Aug
- Castration-naive metastatic prostate cancer: reshaping old paradigms.
- Authors: Ratta R, Grassi P, Fucà G, Verzoni E, Procopio G
- Issue date: 2017 Oct
- [ASC-J9 for castration-resistant prostate cancer].
- Authors: Yamashita S, Arai Y
- Issue date: 2014 Dec